Keeping Lung Cancer Under Control: Bob's Immunotherapy Story
Bob was treated for non-small cell lung cancer (NSCLC) in a clinical trial with a checkpoint inhibitor called atezolizumab (Tecentriq). #CIM17 #CancerPatientStories #nsclc
When Bob was diagnosed with non-small cell lung cancer (NSCLC), his wife Julia was so devastated that she cried for several months thinking about her life without him. Bob weighed all his options with his oncologist. After trying chemotherapy, Bob found another treatment that would give him hope—immunotherapy. He enrolled in a clinical trial of a treatment that helps T cells to recognize and attack cancer cells. Six years later, Bob's health is stable and he remains optimistic. Bob and Julia urge others to not give up hope because advances in cancer research are rapidly providing new treatment options. https://www.cancerresearch.org..../patients/immunocomm
This video is presented as part of the Cancer Research Institute 5th Annual Cancer Immunotherapy Month awareness campaign this June 2017. Learn more about cancer immunotherapy and its potential to save more lives at https://www.cancerresearch.org/june
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
-
Category
No comments found